...
首页> 外文期刊>Kidney Research and Clinical Practice >Refractory tertiary hyperparathyroidism after calcimimetics and delayed parathyroidectomy in a kidney transplant recipient
【24h】

Refractory tertiary hyperparathyroidism after calcimimetics and delayed parathyroidectomy in a kidney transplant recipient

机译:肾移植受者拟钙剂和延迟甲状旁腺切除术后难治性第三甲状旁腺功能亢进

获取原文
           

摘要

Persistent hyperparathyroidism affects renal outcomes and mortality. After kidney transplantation, cinacalcet is not approved as treatment for hyperparathyroidism. Parathyroidectomy, on the other hand, reverses electrolytes and mineral bone metabolism in almost all cases. Early parathyroidectomy may increase the chance of resolving hyperparathyroidism. A 58-year-old man with ESRD status post deceased donor kidney transplantation 3 years prior presented with bone aches. He had persistent hypercalcemia and hypophosphatemia secondary to hyperparathyroidism. Serum calcium ranged 9.3-11.4mg/dl and serum phosphorus was decreased with a lowest value of 2.1mg/dl. Intact PTH level was elevated to 487pg/ml and total 25-OH vitamin D was 20ng/ml. Bone density studies indicated osteopenia. He refused parathyroidectomy and was treated with cinacalcet. Because of persistent hyperparathyroidism, he underwent subtotal parathyroidectomy. Postoperatively, he required high phosphorus diet, phosphate supplements, and cinacalcet to maintain normal serum phosphorus levels. Intact PTH was still elevated with the level of 188pg/ml while he continued cinacalcet. Normally, parathyroidectomy is performed 1 year posttransplantion unless severe bone disease, refractory hypercalcemia, or difficulty controlling phosphate wasting occurs. Phosphate wasting from hyperparathyroidism in our patient indicated parathyroidectomy; however, the surgery was delayed for 3 years while cinacalcet had been used. Post parathyroidectomy, hyperparathyroidism still persisted. Both cinacalcet and parathyroidectomy are imperfect to reverse hyperparathyroidism. Timely parathyroidectomy may determine the reversal of electrolyte and metabolic bone diseases; however, a delayed procedure may not have the same benefit. Since hyperparathyroidism is associated with higher incidence of kidney allograft dysfunction and postoperative mortality, should there be a level where pretransplant parathyroidectomy is performed?
机译:持续性甲状旁腺功能亢进会影响肾脏预后和死亡率。肾脏移植后,西那卡塞未获批准用于甲状旁腺功能亢进症的治疗。另一方面,在几乎所有情况下,甲状旁腺切除术都会逆转电解质和骨矿物质的新陈代谢。早期甲状旁腺切除术可能会增加解决甲状旁腺功能亢进的机会。一名58岁的ESRD病患,在3岁之前死于供体肾脏移植后,出现骨痛。他患有继发性甲状旁腺功能亢进的持续性高钙血症和低磷血症。血清钙范围为9.3-11.4mg / dl,血清磷降低,最低值为2.1mg / dl。完整的PTH水平提高到487pg / ml,总25-OH维生素D为20ng / ml。骨密度研究表明骨质减少。他拒绝甲状旁腺切除术,并接受西那卡塞治疗。由于持续性甲状旁腺功能亢进,他接受了次全甲状旁腺切除术。术后,他需要高磷饮食,磷酸盐补充剂和西那卡塞维持正常的血清磷水平。当他继续西那卡塞时,完整的PTH仍以188pg / ml的水平升高。通常,除非发生严重的骨病,难治性高钙血症或难以控制磷酸盐消耗,否则在移植后1年进行甲状旁腺切除术。本例患者甲状旁腺功能亢进引起的磷酸盐消耗表明甲状旁腺切除术。然而,在使用西那卡塞的同时,手术被推迟了3年。甲状旁腺切除术后,甲状旁腺功能亢进仍然持续。西那卡塞和甲状旁腺切除术均不能逆转甲状旁腺功能亢进。及时进行甲状旁腺切除术可能决定电解质和代谢性骨疾病的逆转;但是,延迟程序可能不会带来相同的好处。由于甲状旁腺功能亢进症与同种异体肾功能不全和术后死亡率更高相关,因此是否应进行移植前甲状旁腺切除术的水平?

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号